Invention Grant
![Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists](/docs/US/2017-06-13/US09676761B2/abs.jpg.600x600.jpg)
- Patent Title: Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
-
Application No.: US14757491Application Date: 2014-06-24
-
Publication No.: US09676761B2Publication Date: 2017-06-13
- Inventor: Olivier Corminboeuf , Sylvaine Cren , Davide Pozzi
- Applicant: ACTELION PHARMACEUTICALS LTD
- Applicant Address: CH Allschwil
- Assignee: ACTELION PHARMACEUTICALS, LTD.
- Current Assignee: ACTELION PHARMACEUTICALS, LTD.
- Current Assignee Address: CH Allschwil
- Agency: Arent Fox LLP
- Priority: WOPCT/IB2013/055220 20130625
- International Application: PCT/EP2014/063243 WO 20140624
- International Announcement: WO2014/206966 WO 20141231
- Main IPC: C07D413/12
- IPC: C07D413/12
![Difluoroethyl-oxazole substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists](/abs-image/US/2017/06/13/US09676761B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to difluoroethyl-oxazole substituted bridged spiro[2.4] heptane derivatives of formula (I), wherein the substituents at the piperidine ring are in trans-arrangement, their preparation and their use as pharmaceutically active compounds.
Public/Granted literature
- US20160289221A1 Difluoroethyl-oxazole sustituted bridged spiro[2.4]heptane derivatives as alx receptor agonists Public/Granted day:2016-10-06
Information query
